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to kill especially difficult-to-treat S. aureus biofilms. S. aureus grown in anoxia and respiration-140 deficient S. aureus small colony variants (SCVs) both exhibit high tolerance to many classes of 141 antibiotics (57-59), likely because the bacteria need to be actively growing in order for many 142 antibacterial compounds to be effective. Depending on the antibiotic class, either the antibiotic 143 target needs to be produced or electron transport is required for drug uptake (57, 60), but 144 membrane-targeting agents are an exception; the target is present whether or not the organism is 145 actively growing (61). Indeed, P. aeruginosa supernatant increased the efficacy of chloroxylenol 146 against S. aureus Newman biofilms to similar degrees in anoxia and normoxia ( Fig. 2A) . 147
148
To test whether the combination of P. aeruginosa supernatant and chloroxylenol is effective 149 against biofilm-grown S. aureus SCVs, we used a S. aureus Col strain that has a mutation in 150 hemB, a gene involved in hemin biosynthesis. The S. aureus hemB mutant is defective in electron 151 transport and has the typical characteristics of clinical SCVs (62). We observed that P. 152 aeruginosa supernatant enhanced chloroxylenol's activity against the Col hemB mutant as well 153 as the parental strain ( Fig. 2B) . 154 Furthermore, we tested whether more mature S. aureus biofilms could be effectively targeted by 156 the P. aeruginosa supernatant-chloroxylenol combination. When we grew S. aureus Newman 157 biofilms for 24 h before exposure to the combination treatment, we observed a striking 4 log-fold 158 enhancement of chloroxylenol's antimicrobial activity (Fig. 2C) , similar to what was seen for 6 159 h-grown biofilms (Fig. 1) . 160
161
The P. aeruginosa exoproducts HQNO and siderophores increase S. aureus biofilm and 162 planktonic sensitivity to chloroxylenol. To explore the mechanism underlying 163 P. aeruginosa supernatant-mediated enhancement of chloroxylenol's anti-staphylococcal 164 activity, we sought to identify P. aeruginosa mutants that were unable to increase the sensitivity 165 of S. aureus Newman biofilms to this drug. Previously, we showed that 2-n-heptyl-4-166 hydroxyquinoline N-oxide (HQNO) and siderophores contribute to the ability of P. aeruginosa-167 to protect S. aureus from vancomycin (37). Thus, we tested P. aeruginosa PA14 strains with 168 mutations in genes encoding components of the Pseudomonas quinolone signal (PQS) quorum 169 sensing system (pqsA, pqsH, pqsL), and biosynthesis of the siderophores pyoverdine (pvdA) and 170 pyochelin (pchE). Supernatants from P. aeruginosa PA14 ∆pqsA, ∆pqsH, ∆pqsL, and ∆pvdA 171 ∆pchE mutants each had a defect in the ability to increase S. aureus Newman biofilm sensitivity 172 to chloroxylenol relative to the wild-type P. aeruginosa PA14 (Fig. S2A, B) . 173 174 Additionally, we tested P. aeruginosa PA14 strains with mutations in genes encoding the 175 following secreted products: hydrogen cyanide (hcnA, hcnB), LasA protease (lasA), elastase 176 (lasB), and rhamnolipids (rhlA). Supernatants from these mutants retained the ability to increase 177 the sensitivity of S. aureus biofilms to chloroxylenol ( Fig. S2A, B) . 178
To investigate whether HQNO, pyoverdine, and pyochelin all contributed to the phenotype, we 180 tested whether the supernatant from P. aeruginosa strains with mutations in the genes encoding 181 all three factors was deficient in enhancing chloroxylenol's activity against S. aureus. Indeed, 182 supernatant from the P. aeruginosa PA14 ∆pqsL ∆pvdA ∆pchE mutant (designated the ∆∆∆ 183 mutant) was unable to increase the sensitivity of S. aureus Newman biofilms to chloroxylenol 184 ( Fig. S2B, 3A) . Supernatant from the P. aeruginosa PA14 ∆pqsL ∆pvdA ∆pchE mutant was 185 unable to potentiate the ability of chloroxylenol to kill difficult-to-treat SCVs and 24 h-grown 186 biofilms ( Fig. 2B we performed a biofilm disruption assay using commercially available HQNO. We used 196 concentrations of HQNO that are in the range of those produced by P. aeruginosa PA14 under 197 our experimental conditions (37), as well as those produced by stationary-phase P. aeruginosa 198 cultures grown in rich media (63, 64). Previously, we quantified the level of HQNO produced by 199 P. aeruginosa PA14 after 24 h of growth in minimal medium on plastic plates, which is the 200 source of P. aeruginosa supernatants used throughout this study (37). We found that the level of 201 HQNO in these P. aeruginosa supernatants is ~10 μg/ml. Additionally, P. aeruginosa PA14 202 produced ~15 μg/ml HQNO when grown on CF-derived epithelial cells for 6 h (37). We 203 observed a dose-response whereby increasing concentrations of exogenous HQNO corresponded 204 with enhanced ability of chloroxylenol to kill S. aureus Newman biofilms (Fig. 3C ). These 205 results indicate that the presence of a single secreted factor, HQNO, is sufficient to alter S. 206 aureus biofilm sensitivity to chloroxylenol. 207 208 HQNO likely does not increase S. aureus sensitivity to chloroxylenol via inhibition of the 209 electron transport chain. HQNO is well known to inhibit Complex II and III of the S. aureus 210 electron transport chain (ETC) (65-68). To investigate whether HQNO shifts S. aureus 211 sensitivity to chloroxylenol by inhibiting respiration, we tested the following ETC inhibitors: 3-212
Nitropropionic acid (3-NP; Complex II inhibitor), Antimycin A (Complex III inhibitor), sodium 213 azide (azide; Complex IV inhibitor), and Oligomycin (ATP synthase inhibitor) or mutations in 214 components of ATP synthase. All but one of the compounds tested, Antimycin A, had little to no 215 impact on S. aureus sensitivity to chloroxylenol, nor did mutations in the ATPase (Fig. S3A -E). 216 217 It is possible that HQNO and Antimycin A are changing antibiotic sensitivity not by inhibiting 218 the ETC, but via a different mechanism entirely. Thus, we took a different approach to 219 investigate whether ETC inhibition changes S. aureus susceptibility to chloroxylenol. Exposure 220 to anoxic conditions is a way to inhibit respiration that does not require the use of chemical 221 compounds. Anoxia did not enhance chloroxylenol's efficacy against S. aureus Newman 222 biofilms in the absence of P. aeruginosa supernatant ( Fig. 2A ). Also, despite lacking a functional 223 ETC, S. aureus SCVs are not hypersensitive to chloroxylenol (Fig. 2B ). Furthermore, as we observed above, P. aeruginosa supernatant is able to potentiate the activity of chloroxylenol to 225 kill SCVs even though these cells are respiration-deficient ( Fig. 2B ). Together, these data 226 indicate that HQNO likely alters S. aureus antibiotic sensitivity via a mechanism independent of 227 its effects on the ETC. 228
229
We next considered several possible mechanisms underlying HQNO-mediated enhancement of 230 chloroxylenol's anti-staphylococcal activity. Specifically, we tested the following models: 1) 231 HQNO-mediated changes in membrane potential increase antibiotic sensitivity, 2) HQNO-232 induced generation of reactive oxygen species leads to enhanced bacterial killing, 3) HQNO 233 alters the ability of S. aureus to efflux chloroxylenol, and/or 4) HQNO changes properties of the 234 S. aureus cell membrane. Experiments testing the first three of these models, which did not 235 support these models, are presented in the Supplemental Results (Text S1) and in Figures We used benzyl alcohol, a well-established membrane fluidizing agent (73-75), as a positive 248 control. Exposure to 500 mM or 1 M of benzyl alcohol for 1 h led to a significant decrease in 249
Laurdan GP relative to S. aureus exposed to MEM, indicating an increase in membrane fluidity 250 ( Fig. 4A ). We observed that treatment of S. aureus Newman with HQNO at all concentrations 251 tested led to a significant reduction in Laurdan GP relative to exposure to MEM alone, indicating 252 that HQNO has a fluidizing effect on the S. aureus membrane ( Fig. 4B ). Additionally, we found 253 that exposure to Antimycin A also led to a significant increase in fluidity ( Fig. 4C ), albeit to a 254 lesser extent than HQNO ( Fig. 4B ). Furthermore, we showed that the solvents for HQNO and 255
Antimycin A, DMSO and ethanol, respectively, did not cause the observed increase in S. aureus 256 membrane fluidity ( Fig. 4B, C) . 257 258 Shifting membrane fluidity alters S. aureus biofilm sensitivity to chloroxylenol. Next, we 259 investigated whether the observed HQNO-mediated increase in membrane fluidity can lead to 260 increased sensitivity to chloroxylenol. To test this hypothesis, we exposed S. aureus biofilms to 261 various compounds that are known to influence membrane fluidity. Benzyl alcohol and 1-262 heptanol both impart higher fluidity, whereas dimethyl sulfoxide (DMSO) causes membranes to 263 become less fluid (73-77). We observed that benzyl alcohol and 1-heptanol both increase S. 264
aureus Newman biofilm sensitivity to chloroxylenol ( Fig. 5A, B) . In contrast, the membrane-265 rigidifying agent DMSO did not increase S. aureus Newman biofilm sensitivity to chloroxylenol 266 ( Fig. 5C ). These results suggest that alterations in S. aureus membrane fluidity impact sensitivity 267 to chloroxylenol, whereby increased fluidity leads to higher sensitivity. 268
Next, we showed that manipulating S. aureus fatty acid composition either by adding exogenous 270 unsaturated fatty acids ( Fig S5A, Text S1) or increasing the proportion of branched-chain fatty 271 acids (BCFAs) relative to short chain fatty acids by mutation (SCFAs; Fig. S5B , Text S1) leads 272 to increased S. aureus sensitivity to chloroxylenol. Additionally, we showed that decreasing 273 levels of BCFAs relative to SCFAs by introducing the lpd mutation does not increase sensitivity 274 to chloroxylenol (Fig. S5C ), and that cardiolipin is not required for altered S. aureus sensitivity 275 to this drug ( Fig. S5D , Text S1). Briefly, S. aureus Newman cells were exposed to medium alone (MEM + L-Gln) or P. 287 aeruginosa PA14 wild-type supernatant for differing lengths of time (30 min, 1 h, 3 h, 6 h, or 10 288 h). Subsequently, fatty acid methyl ester (FAME) analysis was performed to measure the 289 membrane fatty acid composition. 290 291 By 30 min or 1 h, the membrane fatty acid profile of S. aureus cells grown in medium alone 292 appeared similar to the profile of P. aeruginosa supernatant-exposed S. aureus cells ( Fig. S6A -C, 293 Table S3 ). However, prolonged treatment with P. aeruginosa supernatant led to a shift in S. 294 aureus membrane fatty acid profiles. In particular, S. aureus cells incubated with P. aeruginosa 295 exoproducts for 24 h had significantly reduced relative BCFA levels compared to S. aureus 296 grown in medium alone ( Fig. S6D -E, Text S1). Above, we found that HQNO significantly 297 increases S. aureus membrane fluidity after 1 h (Fig. 4B ). Because the fluidizing effect of HQNO 298 occurs more rapidly compared to the effect of P. aeruginosa supernatant on S. aureus membrane 299 fatty acid composition, it is likely that the HQNO-mediated increase in S. aureus membrane 300 fluidity we observe does not occur via changes in membrane fatty acid profiles. 301 302 P. aeruginosa supernatant increases S. aureus biofilm sensitivity to multiple membrane-303 targeting compounds. Given the effects of P. aeruginosa exoproducts on S. aureus sensitivity 304 to chloroxylenol, we explored whether P. aeruginosa alters the anti-staphylococcal efficacy of 305 other membrane-active antibiotics. Here, we tested the efficacy of the phenol-based antiseptic 306 biphenyl, as well as the topical peptide antibiotic gramicidin in combination with P. aeruginosa 307 supernatant. Both of these compounds are thought to kill bacteria by ultimately causing an 308 increase in cell membrane permeability. We discovered that P. aeruginosa secreted products 309 enhance the ability of the membrane-active drugs biphenyl and gramicidin to kill S. aureus 310 Newman biofilms ( Fig. 6A, B ). We also made the interesting observation that P. aeruginosa 311 supernatant increases S. aureus biofilm sensitivity to two non-traditional antibiotics, 312 trifluoperazine, an antipsychotic, and amitriptyline, an antidepressant ( Fig. 6C, D) . Strikingly, 313
the combination of either of these drugs and P. aeruginosa supernatant led to a 2.5 to 3-log 314 reduction in S. aureus biofilm viability compared to exposure to the drug alone ( Fig. 6C, D) . 315 Supernatants from P. aeruginosa PA14 ∆pqsL and ∆pvdA ∆pchE mutants each had defects in the 316 ability to increase S. aureus Newman biofilm sensitivity to trifluoperazine and amitriptyline 317 relative to the wild-type P. aeruginosa PA14 (Fig. 6C, D) , suggesting that HQNO and 318 siderophores both contribute to this phenotype. In contrast, it appears than another P. 319 aeruginosa-produced factor is involved in enhancing the activity of gramicidin against S. aureus 320 biofilms (Fig. 6B) . 321 322 Additionally, we examined whether altering membrane fluidity influenced S. aureus biofilm 323 sensitivity to the above compounds. We observed that benzyl alcohol did not appreciably alter S. 324 aureus sensitivity to gramicidin, trifluoperazine, or amitriptyline ( Fig. 6B-D) . In contrast, the 325 fluidizing agent led to a striking increase in the antibacterial efficacy of biphenyl; the 326 combination of these compounds led to a decrease in S. aureus Newman biofilm viability to 327 below the level of detection of this assay (~200 CFU/ml, Fig. 6A ). These results suggest that a 328 more fluid membrane increases the susceptibility of S. aureus biofilms to biphenyl, which is a 329 compound similar to chloroxylenol in structure and function. 330 331 Finally, we tested whether P. aeruginosa secreted products could increase the anti-332 staphylococcal efficacy of octenidine dihydrochloride, a surfactant-based antiseptic that is 333 approved for treatment of wound infections and has low cytotoxicity (78, 79). We observed that 334 P. aeruginosa supernatant potentiates the activity of octenidine against S. aureus biofilms by 2.5 335 logs (Fig. 6E) . 336
Discussion 338
In this study, we found that the interactions between two bacterial pathogens that are frequently 339 co-isolated from infections can cause striking and unexpected changes in antimicrobial 340 susceptibility profiles. We showed that P. aeruginosa potentiates the ability of various 341 antibacterial agents to kill S. aureus biofilms, which are often difficult to eradicate. In particular, 342
we found that P. aeruginosa secreted products increase the sensitivity of S. aureus biofilms to 343 the topical antiseptic chloroxylenol. Alone, chloroxylenol at a concentration of 100 g/ml is not 344 effective at eradicating S. aureus biofilms; however, in combination with P. aeruginosa cell-free 345 culture supernatant, which alone does not impact S. aureus viability, the efficacy of 346 chloroxylenol increased 4 log-fold. Moreover, we have shown that P. aeruginosa supernatant 347
can increase the ability of chloroxylenol to kill multiple strains and clinical isolates of S. aureus. 348
Furthermore, we found that the small molecule HQNO and the siderophores pyoverdine and 349 pyochelin contribute to the P. aeruginosa-mediated increase in the efficacy of chloroxylenol 350 against S. aureus biofilms. In addition, we showed that HQNO alone recapitulated the effect of 351 P. aeruginosa supernatant. Thus, the addition of a small molecule alone can greatly influence the 352 efficacy of this antiseptic. 353
354
Previous studies have detected HQNO in expectorated sputum from CF patients infected with 355 P. aeruginosa, and these levels are highly variable (29, 80). P. aeruginosa isolates from chronic 356
CF pulmonary infections frequently have loss-of-function mutations in the quorum sensing 357
regulator lasR, and often overproduce alginate (81, 82). LasR inactivity and mucoidy each can 358 lead to decreased HQNO production in vitro (64, 83). Therefore, quorum sensing activity and 359 mucoidy may modulate the levels of HQNO produced by P. aeruginosa during infection, and in 360 turn, influence the ability of HQNO to modify S. aureus drug sensitivity profiles in vivo. 361 362 HQNO has been shown to inhibit the S. aureus electron transport chain (ETC) (65). To 363 investigate whether HQNO influences S. aureus susceptibility to chloroxylenol via inhibition of 364 respiration, we treated S. aureus with chemical inhibitors of the ETC alone or in combination 365 with the antibiotic. We found that only a subset of the ETC inhibitors tested increased the 366 efficacy of chloroxylenol. However, anoxia did not increase S. aureus chloroxylenol sensitivity 367 in the absence of HQNO. Additionally, despite having a defective ETC, S. aureus SCVs became 368 more susceptible to chloroxylenol in the presence of HQNO, suggesting that inhibition of 369 respiration is not required for this phenotype. 370
371
Since it is known that changes in membrane lipid profiles impact sensitivity to membrane-372 targeting compounds (69), we hypothesized that HQNO might cause heightened susceptibility to 373 chloroxylenol by altering one or more properties of the S. aureus cell membrane. Like other 374 phenol-based antiseptics, chloroxylenol is thought to insert into the cell membrane and cause an 375 increase in membrane fluidity and permeability (54-56). Thus, an increase in membrane fluidity 376 mediated by HQNO may allow for greater accumulation of chloroxylenol within the membrane, 377 and subsequently cause an increase in efficacy of the antibiotic. Manipulating the fluidity of E. 378 coli membranes has been previously demonstrated to alter sensitivity to phenols, whereby 379 decreasing membrane fluidity conferred increased tolerance to these compounds (69). Therefore, 380
we tested whether HQNO changes the fluidity of the S. aureus cell membrane, potentially 381 explaining the increased antimicrobial sensitivity we observe. We found that exogenous HQNO 382 causes a striking increase in S. aureus membrane fluidity. Due to its hydrophobic character, it is 383 plausible that HQNO directly interacts with the membrane to increase fluidity. In light of this 384 result, we hypothesized that Antimycin A and Oligomycin, both hydrophobic compounds, also 385 increase S. aureus sensitivity to chloroxylenol by altering membrane fluidity; the other ETC 386 inhibitors tested, 3-NP and sodium azide, which did not enhance sensitivity to chloroxylenol, are 387 both hydrophilic compounds. We showed that treatment of S. aureus with Antimycin A also 388 leads to an increase in membrane fluidity. These findings suggest that the observed HQNO-389 mediated increase in antibiotic efficacy is independent of the effect of HQNO on the S. aureus 390
ETC. Furthermore, we showed that modulating membrane fluidity via either genetic or chemical 391 approaches shifts S. aureus chloroxylenol sensitivity profiles. Together, these results are 392 consistent with a model whereby HQNO increases S. aureus membrane fluidity, which greatly 393 enhances the ability of chloroxylenol to kill S. aureus biofilms. 394
395
We also found that treatment with P. aeruginosa supernatant or pure HQNO influenced the 396 membrane fatty acid composition of S. aureus. Specifically, S. aureus grown in medium alone 397 had a significantly higher proportion of BCFA compared to S. aureus cells exposed to P. 398 aeruginosa supernatant or HQNO for 24 h. Given these results, we hypothesize that HQNO-399 mediated inhibition of the S. aureus ETC leads to decreased rates of fatty acid synthesis. 400
Previous work from our laboratory has shown that when these organisms are in co-culture, P. 401 aeruginosa forces S. aureus to grow by fermentation (84), which leads to a reduction in growth 402 of S. aureus (37). Furthermore, during co-culture with P. aeruginosa, S. aureus downregulates 403 multiple genes involved in fatty acid synthesis, including the cardiolipin synthase (cls1), and 404 branched-chain amino acid transporters (brnQ1, brnQ2, brnQ3, bcaP) (84). Additionally, it has 405 been shown that anaerobically-grown S. aureus has lower protein synthesis rates for multiple 406 enzymes involved in metabolism, including FabG1, which is required for fatty acid synthesis 407 (85). 408 409 Together, our results are consistent with the following two models, which are not mutually 410 exclusive: 1) HQNO increases S. aureus membrane fluidity, potentially via direct interaction 411 with the membrane, and 2) exposure to HQNO slows or halts S. aureus fatty acid synthesis, 412 leading to altered membrane lipid composition, perhaps via ETC inhibition. Our data suggest 413 that the first model may explain how HQNO potentiates the activity of chloroxylenol against S. 414 aureus biofilms. In contrast, our data do not support a role for the second model in explaining the 415 altered chloroxylenol susceptibility profiles we observe. Specifically, the HQNO-mediated 416 increase in S. aureus membrane fluidity occurs more rapidly compared to the P. aeruginosa 417 supernatant-induced changes in fatty acid profiles. Therefore, we hypothesize that HQNO 418 increases fluidity via direct interaction with the membrane, rather than via inducing a shift in 419 membrane fatty acid composition. The second model could explain other potential consequences 420 of this interspecies interaction, such as an impaired ability to adapt to changing environmental 421 conditions. 422
423
We observed that P. aeruginosa exoproducts can potentiate the activity of multiple membrane-424 active compounds, including the phenol biphenyl, and gramicidin, which forms channels within 425 the membrane (86-88). Interestingly, we also showed that P. aeruginosa-secreted factors 426 enhanced the activity of two non-traditional antibiotics, trifluoperazine and amitriptyline. Both of 427 these drugs have a fused tricyclic structure, and have been found to possess antibacterial activity 428 (89-93). Additionally, trifluoperazine was found to synergize with fluconazole against multiple 429 fungal species (94). Due to its high degree of hydrophobicity, trifluoperazine has been shown to 430 interact with cell membranes and cause increased fluidity and permeability (95, 96); it has been 431 hypothesized that amitriptyline acts in a similar manner (93). 432 433 Importantly, we found that the combination of P. aeruginosa supernatant and chloroxylenol was 434 effective against multiple slow-growing S. aureus populations, namely, anaerobically-grown 435 biofilms and SCVs. From a therapeutic perspective, these results could have important 436 implications. Infection sites can have steep oxygen gradients (97, 98), which may lead to slow 437 microbial growth in vivo (99). Slow-growing pathogens are difficult to eradicate because many 438 antibiotic classes are only effective against actively growing cells; in contrast, antibacterial 439 agents that target membranes are effective whether or not bacteria are growing. Thus, our 440 discovery that an interspecies interaction can potentiate the activity of membrane-active drugs 441 could be used to inform the treatment of recalcitrant mixed-species infections involving bacterial 442 biofilms in oxygen-depleted sites. 443
444
Overall, our work demonstrates that polymicrobial interactions can profoundly shift the 445 antibiotic sensitivity profiles of bacteria growing as biofilms. In particular, we discovered that 446 interspecies interactions can lead to changes in the fluidity and composition of the bacterial cell 447 membrane, which may influence other aspects of bacterial physiology as well as responses to 448 environmental stressors. Together, these findings may have important consequences for the 449 treatment of polymicrobial infections in multiple disease contexts, including non-healing wounds 450 and pulmonary infections in patients with cystic fibrosis. Finally, the knowledge we have gained 451 from this work has the potential to inform the development of more effective anti-biofilm 452 combination therapies. 453
Materials and Methods 454
See the Supplemental Materials and Methods in Text S1 for additional details regarding the 455 methods. 456 457 Bacterial strains and culture conditions. A list of all strains used in this study is included in 458 Biofilm disruption assays on plastic were performed with the specified S. aureus clinical 806 isolate, P. aeruginosa PA14 supernatant (Pa sup), and chloroxylenol (Chlor) at 807 100 μg/ml. Biofilms were grown for 6 hours, exposed to the above treatments for 18 hours, and 808 (Chlor) at 100 μg/ml under normoxic or anoxic conditions. Biofilms were grown for 6 hours, 817 exposed to the above treatments for 18 hours, and S. aureus biofilm CFU were determined. (B) 818
Biofilm disruption assays on plastic were performed with S. aureus (Sa) Col parental strain or 819 hemB mutant, supernatants from wild-type P. aeruginosa PA14 and the ∆pqsL ∆pvdA ∆pchE 820 mutant (Pa  sup), and chloroxylenol (Chlor) at 100 μg/ml. Biofilms were grown for 6 hours, 821 exposed to the above treatments for 18 hours, and S. aureus biofilm CFU were determined. (C) 822
Biofilm disruption assays on plastic were performed with S. aureus (Sa) Newman, supernatants 823 from wild-type P. aeruginosa PA14 and the ∆pqsL ∆pvdA ∆pchE mutant (Pa  sup), and 824 chloroxylenol (Chlor) at 100 μg/ml. Biofilms were grown for 24 hours, exposed to the above 825 treatments for 24 additional hours, and S. aureus biofilm CFU were determined. Each column 826 displays the average from three biological replicates, each with three technical replicates. Error 827 bars indicate SD. bd, below detection. ns, not significant; *, P < 0.05, **, P < 0.01, ***, P < 828 0.001, by ordinary one-way ANOVA and Tukey's multiple comparison post-test. wild-type and the ∆pqsL ∆pvdA ∆pchE deletion mutant (Pa  sup), and chloroxylenol (Chlor) 834 at 100 μg/ml. Biofilms were grown for 6 hours, exposed to the above treatments for 18 hours, 835 and S. aureus biofilm (A) and planktonic (B) CFU were determined. Data in panels A and B 836 were from the same experiments. (C) Biofilm disruption assays on plastic were performed 837 with S. aureus (Sa) Newman, chloroxylenol (Chlor) at 100 μg/ml, and the specified 838 concentrations of HQNO (dissolved in DMSO). Biofilms were grown for 6 hours, exposed to the 839 above treatments for 18 hours, and S. aureus biofilm CFU were determined. Each column 840 displays the average from at least three biological replicates, each with three technical replicates. 841
Error bars indicate SD. ns, not significant; ***, P < 0.001, by ordinary one-way ANOVA and 842 concentrations, and Antimycin A at 100 μg/ml along with the ethanol control (solvent for 848 Antimycin A) (C). S. aureus was exposed to the above treatments for 1 hour, and GP values 849 were determined. Each column displays the average from at least three biological replicates, each 850 with three technical replicates. Error bars indicate SD. ns, not significant; ***, P < 0.001, by 851 ordinary one-way ANOVA and Tukey's multiple comparison post-test. Newman, chloroxylenol (Chlor) at 100 μg/ml, benzyl alcohol (BnOH) at 50 mM (A), 1-heptanol 856 at 50 mM (B), and dimethyl sulfoxide (DMSO) at 1% and 6% (C). Biofilms were grown for 6 857 hours, exposed to the above treatments for 18 hours, and S. aureus biofilm CFU were 858 determined. Each column displays the average from at least three biological replicates, each with 859 three technical replicates. Error bars indicate SD. ns, not significant; **, P < 0.01, ***, P < 860 0.001, by ordinary one-way ANOVA and Tukey's multiple comparison post-test. performed with S. aureus (Sa) Newman, supernatants from P. aeruginosa PA14 wild-type and 865 the specified mutants (Pa sup), and either Biphenyl at 200 g/ml (A), Gramicidin at 100 g/ml 866 (B), Trifluoperazine at 100 g/ml (C), Amitriptyline at 100 g/ml (D), or Octenidine 867 dihydrochloride (Oct) at 5 g/ml (E). Biofilms were grown for 6 hours, exposed to the above 868 treatments for 18 hours, and S. aureus biofilm CFU were determined. Each column displays the 869 average from at least three biological replicates, each with three technical replicates. Error bars 870 indicate standard deviation (SD). ns, not significant; *, P < 0.05, ***, P < 0.001, by ordinary 871 one-way ANOVA and Tukey's multiple comparison post-test. 
